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Abstract
Background: The evidence base of clinical interventions in paediatric hospitals of developing
countries has not been formally assessed. We performed this study to determine the proportion
of evidence-based therapeutic interventions in a paediatric referral hospital of a developing country
Methods: The medical records of 167 patients admitted in one-month period were revised.
Primary diagnosis and primary therapeutic interventions were determined for each patient. A
systematic search was performed to assess the level of evidence for each intervention. Therapeutic
interventions were classified using the Ellis score and the Oxford Centre for Evidence Based
Medicine Levels of Evidence
Results: Any dehydration due to diarrhoea (59 cases) and pneumonia (42 cases) were the most
frequent diagnoses. Based on Ellis score, level I evidence supported the primary therapeutic
intervention in 21%, level II in 73% and level III in 6% cases. Using the Oxford classification 16%,
8%, 1% and 75% therapeutic interventions corresponded to grades A, B, C, and D
recommendations, respectively. Overall, according to Ellis score, 94% interventions were evidence
based. However, out of the total, 75% interventions were based on expert opinion or basic
sciences. Most children with mild to moderate dehydration (52 cases) were inappropriately treated
with slow intravenous fluids, and most children with non-complicated community acquired
pneumonia (42 cases) received intravenous antibiotics
Conclusions: Most interventions were inappropriate, despite the availability of effective therapy
for several of them. Diarrhoeal dehydration and community acquired pneumonia were the most
common diagnoses and were inappropriately managed. Existing effective interventions for
dehydration and pneumonia need to be put into practice at referral hospitals of developing
countries. For the remaining problems, there is the need to conduct appropriate clinical studies.
Caution must be taken when assigning the level of evidence supporting therapeutic interventions,
as commonly used classifications may be misleading
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Background
Previous studies have shown that medical interventions
based on scientific evidence range from 10 to 80% [1-4].
These studies were performed in a broad spectrum of
patients and settings in developed countries.
In paediatric practice, the proportion of evidence based
interventions reported ranges from 75 to 91% [5-8]. These
studies are clearly relevant to the quality of care in devel-
oped countries, with strong health systems, widely availa-
ble high technology and qualified human resources.
However, health services in developing countries are fre-
quently weak, and they face too often severe lack of expen-
sive technology. In addition, the level of qualification of
health personnel may vary greatly within health facilities,
even at referral level and in urban areas. Moreover, the
prevalent childhood illnesses in developed countries are
not necessarily those prevalent in developing countries.
The assessment of quality of care at referral level for
severely ill children is an important component of the
efforts for reducing the child mortality rate in poor coun-
tries, for reducing the burden on health systems and for
investing money in favour of high priority health inter-
ventions [9,10]. Thus we were prompted to assess the pro-
portion of interventions based on sound scientific base in
a paediatric referral setting of a developing country.
Methods
Referral care provided to children hospitalized in the pae-
diatric department of the Instituto Especializado de Salud
del Niño (IESN) was assessed for evidence base. IESN is a
national paediatric hospital with more than 500 inpatient
beds, serving mostly patients from deprived socioeco-
nomic areas of Lima and inner cities of the country.
The clinical records of 195 children aged 1 month through
16 years old and hospitalized during January 2003 were
initially revised.
One of the investigators (NYC) assessed the clinical
records of children and assigned to each one a primary
diagnosis and one or more primary therapeutic interven-
tions, on the basis of the main clinical features and/or
definitive diagnostic laboratory aids. Patients in whom a
primary diagnosis was not possible to determine or those
without a clear diagnosis were excluded.
The primary intervention was defined as the treatment or
other manoeuvre that represented the most important
attempt to cure, alleviate, or care for the patient in respect
of his or her primary diagnosis [3].
To determine the level of evidence for each primary inter-
vention, Cochrane reviews were searched. If there was not
such a systematic review, a search through PubMed
(MEDLINE) was performed by one of the investigators
(NYC). All Cochrane reviews were searched through their
own search tools. For PubMed, the period of search was
1966 through 2002. The key words used included those
related to the primary diagnosis (e.g., pneumonia). Lim-
its: "Title", "All child: 0–18 years". Publication type was
sequentially searched for "Practice Guideline", "Meta-
Analysis", "Randomized Controlled Trial" and "Review".
Articles in English or Spanish were included. The National
Guideline Clearinghouse was additionally visited for
additional references. Published recommendations for
judging the quality of guidelines were used for deciding
the selection of the guidelines [11]. In addition, Clinical
Evidence was used whenever deemed pertinent.
The level of evidence assigned to interventions was based
on Ellis score (levels I, II and III) and the Oxford Centre
for Evidence Based Medicine Levels of Evidence (grades A,
B, C and D) [3,12]. Ellis score considers one or more inter-
ventions for a given diagnosis as one primary interven-
tion. For comparison purposes we ranked each individual
intervention through Oxford classification.
As a next step to our study, we planned the dissemination
of the results among the hospital policy makers and the
Table 1: Patients excluded because of undefined diagnoses
Diagnosis N° of
patients
Convulsive syndrome 4
Acute obstructive bronchial syndrome 2
Acute rhinopharyngitis 2
Recurrent obstructive bronchial syndrome 2
Severe dehydration (referred from other hospitals)* 2
Acute lymphocytic leukaemia** 2
Unclassified dehydration 1
Emetic syndrome 1
Acute haemolytic anaemia of unknown cause 1
Anaemia of unknown cause 1
Thrombocytopenic purpura of unknown cause 1
Thrombocytopenia of unknown cause 1
Histiocytosis (clinical diagnosis) 1
Secondary epilepsy of unknown cause 1
Simple partial epilepsy of unknown cause 1
Munchausen's Syndrome (unclear criteria) 1
Congenital dyskeratosis 1
Neurocysticercosis (presumptive diagnosis) 1
Mental retardation (unspecified cause) 1
Operated hydrocephalousof unknown cause 1
Total 28
*Patients were fully hydrated upon arrival to IESN.
**Patients were referred to other hospital for definitive management.BMC Health Services Research 2004, 4:40 http://www.biomedcentral.com/1472-6963/4/40
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suggestion of corrective courses of action for those inter-
ventions needing improvement.
Results
Results of the search strategies for PubMed are included as
an appendix [See Additional File 1]. A guideline on man-
agement of pain in sickle cell disease was found in the
National Guideline Clearinghouse website and the results
of the search are also shown at the end of the appendix
[See Additional File 1].
Overall, one hundred and ninety five clinical records were
revised. Twenty eight clinical records were excluded
because of undefined primary diagnosis (Table 1). One
hundred and sixty seven remaining clinical records were
further assessed. The most frequent primary diagnoses are
shown in Table 2, being diarrhoeal dehydration and
pneumonia the main causes for hospitalization. The
childhood prevalent diseases are quite constant through-
out the year at our hospital and thus it is unlikely that the
results would have been different if we had chosen
another study period.
Out of 167 primary interventions, 21% were supported by
level I evidence, 73% were level II, and 6% were ranked as
level III, according to Ellis classification [3]. Table 3 shows
that most interventions classified as level I are referred to
acute asthma exacerbations. Nebulized beta-agonists and
systemic corticosteroids in bronchiolitis, and antibiotics
for acute otitis media were considered level I according to
Ellis. They were classified as D{5} according to Oxford
Centre for Evidence Based Medicine Levels of Evidence
(Table 3) [12].
Most assessed interventions were considered as level II
(Table 4). Diarrhoeal dehydration and community-
acquired pneumonia were the predominant diagnoses.
Considering each prescription separately (fluid restric-
tion, furosemide, spironolactone and captopril in heart
failure, for example) we obtained 146 interventions.
When we assessed them through the Oxford classification,
11% interventions were classified as grade B, 1% as grade
C, and 88% as grade D. Appropriate interventions for the
same diagnoses presented in Table 4 and ranked by
Oxford classification are shown in Table 5.
Overtly unsubstantiated therapy according to Ellis classi-
fication is shown in Table 6. Considering levels I and II
evidence-based therapy, 94% of therapeutic interventions
were evidence based through Ellis classification. Using the
Oxford classification, we obtained 193 individualized
therapeutic interventions, that were classified as Grades A
(16%), B (8%), C (1%), and D (75%).
Comparison of grade of recommendation of the pre-
scribed intervention with the appropriate one is shown in
Table 7. It will be used as summary evidence documenting
our current hospital health care quality standard.
Discussion
In this study 94% of therapeutic interventions were evi-
dence-based by Ellis score. It may seem encouraging that
more than 90% of therapeutic decisions in a referral pae-
diatric hospital of a developing country are evidence
based. However, the level II of evidence from Ellis
includes interventions based in cohort studies, case-con-
trol studies, case series, expert's opinion, and even those
based in basic sciences. We attempted therefore to classify
the primary interventions according to more specific
criteria. Using the Oxford classification, 75% of therapeu-
tic interventions were based in expert opinions or in basic
sciences (Grade of Recommendation D).
Table 2: Definitive diagnoses
Diagnosis N° of
patients
Moderate diarrhoeal dehydration 48
Community acquired pneumonia 42
Acute asthma 22
Severe diarrhoeal dehydration 7
Congestive heart failure 6
Bronchiolitis 5
Mild diarrhoeal dehydration 4
Cellulitis 3
First simple febrile convulsion 3
Hypoxic crisis secondary to cyanotic congenital 
heart disease
3
Haemophilia A 3
Dilated cardiomyopathy 2
Nosocomial pneumonia 2
Post-infectious cerebellitis 1
Sickle cell anaemia vaso-occlusive crisis 1
Croup 1
Acute dysenteric diarrhoea 1
Invasive acute diarrhoea 1
Kawasaki disease 1
Anal fissure 1
Hydrocarbon poisoning 1
Recurrent urinary tract infection 1
Acute bacterial meningitis 1
Aspiration pneumonia 1
Acute otitis media 1
Mild acute pancreatitis 1
Immune thrombocytopenic purpura 1
Status epilepticus 1
Supraventricular tachycardia 1
Trichuriasis 1
Total 167BMC Health Services Research 2004, 4:40 http://www.biomedcentral.com/1472-6963/4/40
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Some limitations of our study include the possible author'
bias when assigning the primary diagnosis and primary
intervention. The assignment of diagnosis by the clinician
may have been influenced by both the choice of treatment
and the available evidence. Only one of us classified the
primary intervention. In addition, we evaluated only a
Table 3: Level I primary interventions (Ellis score) ranked by Oxford classification
Diagnosis Patients Prescribed therapeutic 
intervention
Oxford 
classification
Appropriate therapeutic 
intervention
Oxford 
classification
Reference
Acute asthma 22 Beta 2 agonists-Systemic 
corticosteroids
A{1a} Beta 2 agonists-Systemic 
corticosteroids
A{1a} 13
Bronchiolitis 5 Beta 2 agonists-Systemic 
corticosteroids
D{5} Supportive therapy A{1a} 14
Simple febrile seizure 3 Observation A{1a} Observation A{1a} 15
Cellulitis 2 Oxacillin A{1b} Oxacillin A{1b} 16
Acute otitis media 1 Amoxicillin D{5} Antipyretic/analgesic therapy A{1a} 17
Moderate croup 1 Dexamethasone L-Adrenaline A{1a}, A{1b} Dexamethasone L-
Adrenaline
A{1a}, A{1b} 18
Trichuriasis 1 Albendazole – Mebendazole A{1b} Albendazole – Mebendazole A{1b} 19
Table 4: Level II primary interventions (Ellis score) ranked by Oxford classification
Diagnosis Patients Prescribed therapeutic intervention Oxford classification Reference
Severe dehydration 1 IV ClNa 0.9% bolus, Rehydration in 04 hours D{5}, B{2b} 20
Severe dehydration 6 IV ClNa 0.9% bolus, Rehydration in 24 hours D{5}, D{5} 20
Moderate dehydration 1 IV 80 ml/Kg in 04 hours B{2b} 20
Moderate dehydration 1 IV 80 ml/Kg in 06 hours D{5} 20
Moderate dehydration 43 IV Rehydration in 24 hours D{5} 20
Mild dehydration 4 IV Rehydration in 24 hours D{5} 20
Severe dehydration 6 IV ClNa 0.9% bolus, Rehydration in 24 hours D{5}, D5} 20
CA Pneumonia (<5 years) 33 Ampicillin/Ceftriaxone/Chloramphenicol D{5} 21
CA Pneumonia (<5 years) 2 Ceftriaxone-Oxacillin/Ceftazidime-Vancomycin D{5} 21
CA Pneumonia (<5 years) 1 Ampicillin-Amikacin D{5} 21
CA Pneumonia (>5 years) 4 Penicillin G sodium D{5} 21
CHF 2 Fluid restriction, Furosemide, Captopril, Spironolactone D{5}, D{5}, B{2b}, B{1a} 22, 23, 24
CHF 3 Fluid restriction, Furosemide-Captopril D{5}, D{5}, B{1a} 22, 23, 24
CHF 1 Fluid restriction, Hydrochlorothiazide, Captopril D{5}, D{5}, B{1a} 22, 23, 24
Haemophilia A 3 Cryoprecipitate/Frozen fresh plasma D{5} 25
Cyanotic crisis 2 Meperidine – Ethylephrine D{5} 26
Nosocomial pneumonia 2 Ceftazidime-Vancomycin-Clindamycin D{5} 27
Vaso-occlusive crisis (SCA) 1 Lysine-clonixinate D{5} 28
Dilated cardiomyopathy 1 Lanatoside C-Furosemide-Captopril D{5}, B{2b} 29, 30
Dilated cardiomyopathy 1 Furosemide-Captopril-Spironolactone D{5}, B{2b}, D{5} 29, 30
Status epilepticus 1 Diazepam – Phenytoin B{2a} 31, 32
Bacterial meningitis 1 Ceftriaxone C 33
Dysenteric acute diarrhoea 1 Ceftriaxone B{3b} 34
Invasive acute diarrhoea 1 Ceftriaxone B{3b} 34
Recurrent UTI 1 Ciprofloxacin C 35
Mild acute pancreatitis 1 Soft diet (low in fat) – Ranitidine D{5} 36, 37, 38
Hydrocarbon ingestion 1 Nil per os – Soft diet D{5} 39, 40
PSVT 1 Adenosine B{1b} 41
Aspiration pneumonia 1 Chloramphenicol D{5} 42
Post infectious cerebellitis 1 Acetaminophen D5 43
CA: community acquired; CHF: congestive heart failure; SCA: sickle-cell anaemia; IV: intravenous; ORS: oral rehydration solution; PSVT: paroxysmal 
supraventricular tachycardia.BMC Health Services Research 2004, 4:40 http://www.biomedcentral.com/1472-6963/4/40
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primary intervention for a single primary diagnosis. Actu-
ally, many patients had more than one diagnosis and
obviously more than one therapeutic intervention.
We used as evidence-base for rating the interventions
assessed in our study, guidelines and evidence-based
resources published in the developed world. This raises
the issue of whether they are fully applicable to our
setting. The most prevalent conditions found were diar-
rhoeal dehydration and community acquired pneumonia.
For both of them we used British produced guidelines
[20,21] because there were not Cochrane reviews on them
and because the guidelines fulfilled recommended criteria
for methodological quality of published guidelines [11].
The main recommendation of the guidelines on diarrhoea
favours rapid oral rehydration over intravenous rehydra-
tion for children with mild to moderate dehydration [20].
This recommendation is based on several studies
performed in both developed and developing countries
and thus it can be applicable to both settings. The only
concern on the applicability from setting to setting is that
related to the osmolarity of the oral rehydration solution
(ORS). The guidelines recommend a solution with 60
mmol/l of sodium, whereas a recent expert consensus
found sufficient evidence to recommend the universal use
of an ORS containing 75 mmol/l of sodium [49].
Regarding community acquired pneumonia, the British
guidelines recommend antibiotic treatment for all chil-
dren with pneumonia, due to the difficulties in identify-
ing the aetiology, and they also specify criteria for
hospitalization [21]. These recommendations are in
agreement with the World Health Organization published
guidelines [50]. The main difference is that the WHO
guidelines rest on fast breathing and chest retraction for
the diagnosis of pneumonia, whereas the British
guidelines emphasize the role of chest x-rays. Chest x-rays
are widely available in referral hospitals in developing
countries and thus they should be used in addition to the
clinical findings.
Table 5: Level II primary interventions (Ellis score) and their corresponding appropriate interventions ranked by Oxford 
classification*
Diagnosis Appropriate therapeutic intervention Oxford classification Reference
Severe dehydration IV 20 ml/Kg, 30–80 ml/Kg 3–4 hours D{5}, B{2b} 20
Severe dehydration IV 20 ml/Kg, 30–80 ml/Kg 3–4 hours D{5}, B{2b} 20
Moderate dehydration 30–80 ml/Kg 3–4 hours (ORS) B{2b} 20
Moderate dehydration 30–80 ml/Kg 3–4 hours (ORS) B{2b} 20
Moderate dehydration 30–80 ml/Kg 3–4 hours (ORS) B{2b} 20
Mild dehydration 30–50 ml/Kg 3–4 hours (ORS) B{2b} 20
Severe dehydration IV 20 ml/Kg, 30–80 ml/Kg 3–4 hours D{5}, B{2b} 20
CA Pneumonia (<5 years) Ampicillin/Chloramphenicol/Ceftriaxone D{5} 21
CA Pneumonia (<5 years) Ampicillin/Chloramphenicol/Ceftriaxone D{5} 21
CA Pneumonia (<5 years) Ampicillin/Chloramphenicol/Ceftriaxone D{5} 21
CA Pneumonia (>5 years) Penicillin G/Ceftriaxone/Cefuroxime D{5} 21
CHF Fluid restriction, Spironolactone, Captopril D{5}, B{2b}, B{1a} 22, 23, 24
CHF Fluid restriction, Spironolactone, Captopril D{5}, B{2b}, B{1a} 22, 23, 24
CHF Fluid restriction, Spironolactone, Captopril D{5}, B{2b}, B{1a} 22, 23, 24
Haemophilia A Factor VIII/Cryoprecipitate D{5} 25
Cyanotic crisis Meperidine D{5} 26
Nosocomial pneumonia Broad spectrum antibiotic therapy D{5} 27
Vaso-occlusive crisis (SCA) Ketorolac C{2b} 28
Dilated cardiomyopathy Digoxin-Furosemide, Captopril D{5}, B{2b} 29, 30
Dilated cardiomyopathy Digoxin-Furosemide, Captopril D{5}, B2b} 29, 30
Status epilepticus Diazepam – Phenytoin B{2a} 31, 32
Bacterial meningitis Ceftriaxone C 33
Dysenteric acute diarrhoea Ampicillin/Ceftriaxone B{3b} 34
Invasive acute diarrhoea Ampicillin/Ceftriaxone B{3b} 34
Recurrent UTI Empirical antibiotic therapy C 35
Mild acute pancreatitis Enteral feeding, Antibiotic, H2 Antagonists D{5} 36, 37, 38
Hydrocarbon ingestion Nil per os – Low fat diet D{5} 39, 40
PSVT Adenosine B{1b} 41
Aspiration pneumonia Penicillin/Clindamycin A{1b} 42
Post infectious cerebellitis Intravenous immunoglobulin C4 43
*Diagnoses are the same as in Table 4. CA: community acquired; CHF: congestive heart failure; SCA: sickle-cell anaemia; IV: intravenous; ORS: oral 
rehydration solution; PSVT: paroxysmal supraventricular tachycardia.BMC Health Services Research 2004, 4:40 http://www.biomedcentral.com/1472-6963/4/40
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We acknowledge that the evidence derived from studies
performed in developed countries should be translated
with caution to developing settings. However, when the
native research is scarce or of low quality, we think that
the transfer of knowledge from the developed countries is
an acceptable approach, as far as the particular character-
istics of patients in developing countries are considered
on an individual basis.
Dehydration due to diarrhoea and pneumonia were the
most frequent diagnoses. Oral rehydration for diarrhoeal
dehydration and antibiotics for pneumonia are consid-
ered as interventions with sufficient evidence for imple-
menting them widely [9,10]. In our study, all children
with mild to moderate dehydration were treated with
slow intravenous infusion, and most children with
uncomplicated community acquired pneumonia received
intravenous antibiotics.
In addition to their enormous potential for saving lives,
outpatient antibiotic therapy for pneumonia and outpa-
tient oral rehydration can drastically reduce the rate of
hospitalizations, the hospital stay, the hospital mortality
rate, and the costs incurred. At our hospital, the mean stay
time for hospitalized children is 4.7 days, and the mean
crude mortality rate is 3.6%. We estimated the cost of
managing hospitalized children with pneumonia and
diarrhoeal dehydration as US$ 10.6/day and US$ 8.6/day,
respectively. These costs are referred only to hospital bed
and laboratory tests. A substantial amount of money
could be saved treating these conditions on an outpatient
basis.
Table 6: Level III primary interventions (Ellis score) ranked by Oxford classification
Diagnosis Patients Prescribed 
therapeutic 
intervention
Oxford 
classification
Appropriate 
therapeutical 
intervention
Oxford 
classification
Reference
Moderate dehydration 3 IV 0.9% ClNa bolus – 
Time of rehydration: 
24 hours
D Oral rehydration solution, 
30–80 cc/Kg in 3–4 hours
B{2b} 20
Community acquired 
pneumonia (<5 years)
2 Antibiotic therapy <3 
days
D Ampicillin/
Chloramphenicol/
Ceftriaxone
D{5} 21
Cyanotic crisis due to 
cyanotic congenital heart 
disease
1 Meperidine, 
Ethylephrine, Oxygen
D{5}, D Meperidine D{5} 26
Facial cellulitis 1 Ceftazidime, 
Vancomycin
D{5} Oxacillin, Cephalosporin D{5} 20
Idiopathic thrombocytopenic 
purpura*
1 Platelets, 
Dexamethasone
D{5} Systemic corticosteroids A{1b} 44
Anal fissure 1 Zinc oxide D Topical anaesthetic or 
glyceryl trinitrate
A{1b} 45, 46
Kawasaki disease 1 Acetylsalicylic acid D Intravenous 
immunoglobulin, 
acetylsalicylic acid
A{1a} 47, 48
*Presenting as haematoma with 15,000 plateles/mm3
Table 7: Therapeutic interventions graded according to Oxford classification
Prescribed intervention Appropriate intervention
Grade of 
recommendation
N° % N° %
A 30 16 38 20
B 16 8 77 41
C 2142
D 1 4 5 7 57 03 7
Total 193 100 189 100BMC Health Services Research 2004, 4:40 http://www.biomedcentral.com/1472-6963/4/40
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We planned the dissemination of our results among the
hospital policy makers. The tools that will be suggested for
improving the standards include the development and
systematic application of locally produced guidelines
and/or the adaptation of published guidelines. A useful
alternative that has been experienced for several years at
our inpatient ward unit is to make available personal
computers connected to Internet for attending physicians,
residents and interns, and to encourage the use of online
evidence-based resources. This last alternative may work
better, particularly where there are motivated physicians
who are able to lead the efforts for improving the health
care standards. However, the ultimate decision to system-
atically introduce and monitor the suggested changes will
rest on hospital managers. Such changes should also
depend on taking into account the role of several other
determinants of the clinical decision making by individ-
ual practitioners, such as continuous training, motivation,
time, availability of drugs, equipments and supplies,
supervision, and long-term health system strengthening
strategies.
Conclusions
Caution must be taken when assigning the level of evi-
dence that supports therapeutic interventions, as com-
monly used classifications may be misleading. Existing
effective interventions for dehydration and pneumonia
are not being implemented in developing countries, even
at referral level, and thus there is the need to change the
current medical interventional behaviours. For the
remaining diagnoses, the majority of assessed interven-
tions were based on weak or non-existent evidence, high-
lighting the need to conduct appropriate clinical studies.
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